Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Athenex Inc    ATNX

ATHENEX INC

(ATNX)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Athenex : New partnership to test oral paclitaxel

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/12/2019 | 03:44am EDT

Athenex, Cancer Research UKs Combinations Alliance and the NIHR Clinical Research Network Industry Alliance have announced a partnership to test a chemotherapy drug that can be taken orally in early phase clinical trials.

The partnership will enable researchers to investigate Athenex innovative experimental drug Oraxol, the first oral formulation of the chemotherapy drug paclitaxel, in combination with other cancer treatments.

Paclitaxel works by blocking the growth of cancer, and is widely used for a range of cancer types, but currently can only be given intravenously through a drip.

The ability to take paclitaxel orally would expand opportunity for patients to have their treatment at home, rather than travelling to hospital regularly, and may reduce treatment delivery costs for health services.

Rudolf Kwan, Athenex chief medical officer, said: Oraxol marks a significant step forward for the development of oral chemotherapies, potentially changing the way a large proportion of cancer patients receive chemotherapy treatment.

He continued, By working with Cancer Research UKs Combinations Alliance and NIHR Clinical Research Network, our goal is to develop Oraxol in combinations that would not otherwise be possible, bringing new treatment options to more cancer patients.

The clinical trials managed by this partnership will be academically sponsored and delivered with additional support and oversight from Cancer Research UK and NIHR Clinical Research Network.

Oraxol was recently awarded PIM (Promising Innovative Medicine) designation by the UK`s Medicines and Healthcare products Regulatory Agency (MHRA), indicating that the regulator considers the drug to be a promising candidate for the UKs Early Access to Medicines Scheme, which gives patients with life threatening or seriously debilitating conditions access to medicines before they are approved for use in Europe.

Athenex already has a strong presence in North America and Asia; with the new partnership between Athenex, Cancer Research UK and the NIHR Clinical Research Network Industry Alliance as part of a broader plan to move into Europe.

(c) 2019 TehranTimes. All Rights Reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ATHENEX INC
06/13ATHENEX, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
06/07ATHENEX : Provides an Update on its Chongqing API Plant
AQ
06/07ATHENEX AND PHARMAESSENTIA ANNOUNCE : tirbanibulin) in Patients with Psoriasis
AQ
06/06ATHENEX, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
06/06Athenex Provides an Update on its Chongqing API Plant
GL
06/06ATHENEX AND PHARMAESSENTIA ANNOUNCE : tirbanibulin) in Patients with Psoriasis
GL
05/30Athenex to Present at the 2019 ASCO Annual Meeting
GL
05/09ATHENEX : 1Q Earnings Snapshot
AQ
05/09ATHENEX : Management's Discussion and Analysis of Financial Condition and Result..
AQ
05/09ATHENEX, INC. : Results of Operations and Financial Condition, Financial Stateme..
AQ
More news
Financials ($)
Sales 2019 97,6 M
EBIT 2019 -126 M
Net income 2019 -122 M
Debt 2019 175 M
Yield 2019 -
P/E ratio 2019 -
P/E ratio 2020
EV / Sales 2019 14,9x
EV / Sales 2020 11,9x
Capitalization 1 276 M
Chart ATHENEX INC
Duration : Period :
Athenex Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ATHENEX INC
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Average target price 25,0 $
Spread / Average Target 51%
EPS Revisions
Managers
NameTitle
Yiu Nam Lau Chairman & Chief Executive Officer
Jeffrey M. Yordon COO & President-Athene Pharmaceutical Division
Randoll Sze Chief Financial Officer
Rudolf Kwan Chief Medical Officer
David Cutler Vice President-Clinical Development
Sector and Competitors
1st jan.Capitalization (M$)
ATHENEX INC40.35%1 114
GILEAD SCIENCES7.27%80 909
VERTEX PHARMACEUTICALS4.87%42 680
REGENERON PHARMACEUTICALS-16.74%32 744
GENMAB13.49%10 857
SAREPTA THERAPEUTICS INC21.25%8 523